Fig. 3: Effects of Chidamide and Rituximab in cellular transcriptomes of DLBCL cells. | Cell Death & Disease

Fig. 3: Effects of Chidamide and Rituximab in cellular transcriptomes of DLBCL cells.

From: Novel HDAC inhibitor Chidamide synergizes with Rituximab to inhibit diffuse large B-cell lymphoma tumour growth by upregulating CD20

Fig. 3

a Numbers of genes upregulated (Up) or downregulated (Down) more than twofold than untreated control (NC) after treatment with Chidamide (Chi) or Rituximab (Rit) for 24 h. b Number of genes in different FPKM (fragments per kilobase million) interval (FPKM ≤ 1, 1–10 FPKM, FPKM ≥ 10) in different groups (NC, Chidamide and Rituximab). c, d Heatmap of the differential expression genes (DEGs) in hematopoietic cell lineage pathway (Kyoto Encyclopaedia of Genes and Genomes pathway (KEGG)) in response to Chidamide for 24 h. c Su-DHL8 cell line and d OCI-Ly7 cell line. The red arrow points CD20 mRNA, MS4-A1. e Effects of Chidamide or Rituximab in MS4A1 (CD20 mRNA) expression. The levels of MS4A1 expression was represented as numbers of FPKFs. ‘n.s.’ indicates not significant.

Back to article page